Abstract
Background: At present, the diagnosis of lymphoproliferative disorders is based on the combination of blood or bone marrow smear morphology and immunophenotyping by flow cytometry. Immunophenotypic testing by flow cytometry technique is available only in big medical centers, which is not always convenient for a patient. Therefore, development of an available method for preliminary diagnosis of lymphoproliferative diseases not requiring special equipment seems relevant.Materials and methods: Peripheral blood mononuclear cells from 17 patients admitted to the hospital with suspicion of a lymphoproliferative disorder, and 17 healthy donors were studied on a cell biochip for determination of proportions of cells positive for various surface CD antigens. The diagnosis was verified by flow cytometry.Results: Compared to healthy controls and patients with T-cell lymphoproliferative disorders (TCLPD), the patients with B-cell lymphoproliferative disorders (BCLPD) had significantly lower proportion of CD7+ cells (medians, 7% and 73% respectively, p=2×10-6 for comparison with healthy controls; median 7% and 93% for comparison with TCLPD, p=0.032). In addition, the patients with BCLPD had higher proportion of peripheral СD19+ mononuclear cells, compared to that in the patients with TCLPD and healthy donors (medians 84% and 13% for comparison between BCLPD and healthy control, p=2×10-5; 84% and 3% for comparison of BCLPD and TCLPD, p=0.033). The patients with B-cell chronic lymphocytic leukemia had significantly higher CD5+ cells in the cell biochip compared to the patients with other BCLPD (medians 72% and 9%, p=0.024). The patients with TCLPD had significantly lower proportion of CD19+ cells than the healthy controls (medians, 3% and 13%, respectively, р=0.042).Conclusion: The study has demonstrated the potential to use the previously developed cell biochip for diagnosis of lymphoproliferative diseases. The biochip makes it possible to sort out white blood cells according to their surface differentiation antigen for their further morphological analysis. The cell biochip allows for the differential diagnosis between BCLPD and TCLPD and determination the lymphocyte clones based on the expression of immunoglobulin light chains.
Highlights
the diagnosis of lymphoproliferative disorders is based on the combination of blood or bone marrow smear morphology
Peripheral blood mononuclear cells from 17 patients admitted to the hospital with suspicion
17 healthy donors were studied on a cell biochip for determination
Summary
Мононуклеары периферической крови 17 пациентов, поступивших в стационар с подозрением на лимфопролиферативное заболевание, и 17 здоровых доноров исследовались на клеточном биочипе для определения доли клеток, положительных по различным поверхностным CD-антигенам. Пациенты с Т-ЛПЗ статистически значимо отличались от здоровых доноров более низкой долей СD19+ клеток (медианы 3 и 13% при сравнении пациентов с Т-ЛПЗ и контроля, р = 0,042). Критерии диагностики лимфопролиферативных заболеваний по периферической крови пациентов при помощи клеточного биочипа. Анализ крови при помощи клеточного биочипа может быть использован в медицинских учреждениях любого уровня как метод предварительной диагностики, позволяющий предположить наличие ЛПЗ, или как альтернатива проточной цитометрии в том случае, когда проведение цитометрического анализа по каким-либо причинам невозможно. Цель настоящего исследования – сформулировать критерии определения наличия В-клеточных (В-ЛПЗ) и Т-клеточных лимфопролиферативных заболеваний (Т-ЛПЗ) на основе данных, полученных с помощью клеточного биочипа при обследовании пациентов с подозрением на ЛПЗ, поступивших для первичной диагностики
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
